IPM Take
The strongest signal is that rare disease policy is no longer only about orphan drug access. England is now linking faster diagnosis, genomic testing, coordinated care, health equity, data infrastructure and individualised genetic therapies in one plan. That matters for neurogenetic disease because the hardest access question is often not one medicine. It is whether the system can identify the patient, build the evidence, regulate the therapy, assess value and deliver care for very small populations.
Executive Summary
Published in 2026, the England Rare Diseases Action Plan reports progress against the four UK Rare Diseases Framework priorities: faster diagnosis, greater professional awareness, better care coordination and improved access to specialist care, treatment and drugs. The plan highlights the extension of the UK Rare Diseases Framework to January 2027, recognition of rare disease as a health inequality, development of an NHS framework for individualised genetic therapies, the first NHS patient treated with an individualised therapy, two pilot centres for undiagnosed rare conditions and continued development of the NHS Genomic Medicine Service.
Why it matters
- Policymakers: Need to move rare disease policy beyond isolated treatment access and into diagnosis, data, equity, coordinated care and future therapy readiness.
- Regulators / HTA bodies: Must prepare for therapies designed for one patient or very small patient groups, where conventional evidence and value assessment may not fit.
- Patients / advocates: Should watch whether the plan reduces diagnostic delay, improves care coordination and makes advanced therapies reachable beyond specialist centres.
Before this plan, rare disease policy was often divided into separate problems: diagnostic delay, access to specialists, orphan drug reimbursement, fragmented care and limited data. England’s 2026 plan tries to connect those problems into a wider implementation pathway.
What has changed is the move toward individualised therapy readiness. NHS England is developing a national framework for therapies designed for an individual or a very small number of patients. MHRA and NICE are also being pulled into the same access question: how should rare disease therapies be regulated, assessed and delivered when the evidence base may be highly uncertain?
There is no single eligibility criterion. The affected population includes people living with rare diseases, undiagnosed patients, patients needing genomic testing and patients whose conditions may one day be treated through highly individualised therapies.
The implementation issue is sharp. If individualised therapies are becoming scientifically possible, the access system must be rebuilt around speed, uncertainty, equity and long term follow up. Otherwise, personalised medicine will reach only the rare disease patients whose pathway is already visible.
